Star drugs like BMS' Opdivo, AstraZeneca's Lynparza will get speedy OKs in China this year, new report predicts
Now that China has revamped its drug review process to speed things up for developers, a new report predicts that Bristol-Myers Squibb $BMY, AstraZeneca $AZN and Amgen $AMGN are among the leading multinational pharma giants that will win approval for some blockbuster hopefuls. Others stand to benefit from marketing drugs developed by Chinese partners.
The report, produced by Beijing-based data provider PharmCube, highlights 16 products Chinese regulators are expected to green light in 2018. Over half of them involve an overseas player in biopharma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.